Although a neuroprotective effect of the PERK inhibitor GSK2606414 has been confirmed in multiple models of neurodegenerative diseases [71,72,73], treatment with GSK2606414 triggered a cytotoxic effect, resulting in body weight loss and induction of hyperglycemia in vivo [71]. The gene discussed is EIF2AK3; the disease is Hyperglycemia.